Retinal Dosing Regimen for Visual Function Recovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic regimens for visual disorders associated with endogenous retinoid deficiencies, such as retinitis pigmentosa and Leber congenital amaurosis, face challenges due to the need for frequent administration of synthetic retinal derivatives, which leads to toxicity and undesirable side effects, particularly in young subjects.
Innovation Solution
A dosing regimen involving a first therapeutic dose of a synthetic retinal derivative, followed by a resting period of 7 to 28 days, and a second dose, which minimizes toxicity and improves visual function while maintaining a clinically acceptable safety profile.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If synthetic retinal derivatives are administered frequently to treat visual disorders, then visual function is improved, but toxicity and side effects increase
Solution Approach 1:
The patent implements a dosing regimen with periodic administration of synthetic retinal derivatives, where treatment cycles are interspersed with rest periods. This periodic action maintains therapeutic effectiveness while allowing the body to eliminate accumulated toxic metabolites during rest intervals, thereby resolving the contradiction between continuous visual function improvement and avoidance of toxicity
Solution Approach 2:
The patent incorporates preliminary testing and monitoring phases before full treatment initiation, and includes gradual dose escalation protocols. These preliminary actions allow clinicians to assess individual patient responses and adjust treatment parameters before committing to intensive dosing schedules, preventing excessive toxicity while ensuring adequate visual function improvement
2Object-affected harmful factors
If the dosing interval is extended to reduce toxicity, then side effects decrease, but visual function improvement is reduced
Solution Approach 1:
The patent employs dynamic dosing regimens where the timing and dosage of synthetic retinal derivatives are adjusted based on measured visual function parameters and toxicity markers. This dynamic approach optimizes the balance between maintaining visual improvement and minimizing side effects by adapting the dosing interval to each patient's metabolic rate and response pattern
Solution Approach 2:
The patent systematically varies dosing parameters including frequency, duration, and dosage amount to find the optimal treatment window. By changing these parameters in controlled studies, the patent identifies regimens that extend the effective half-life of the therapeutic compound while limiting the accumulation of toxic metabolites, thus resolving the contradiction between extended intervals and treatment efficacy
3Reliability
If high doses are administered to maximize visual improvement, then visual function increases, but toxic side effects become more severe
Solution Approach 1:
The patent applies partial action by administering doses that are sufficient to achieve therapeutic visual improvement without exceeding the threshold that causes severe toxicity. The dosing regimen is carefully calibrated to provide just enough synthetic retinal derivative to replenish depleted 11-cis-retinal stores and restore visual function, avoiding the excessive doses that would cause severe adverse effects
Solution Approach 2:
The patent incorporates continuous monitoring of visual function parameters and toxicity markers to provide feedback for dose adjustment. This feedback mechanism allows clinicians to identify the optimal dose range for each patient, maximizing visual improvement while staying below the threshold for severe toxic side effects through real-time treatment optimization
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This regimen provides meaningful improvement in vision for subjects with endogenous retinoid deficiencies, as measured by increased visual field and visual acuity, while reducing the severity of toxic side effects and extending the time between treatment cycles.
Implementation Method 1
Vision is sustained by the cycling of all-trans-retinal back into 11-cis-retinal, which occurs by a complex series of biochemical reactions involving multiple enzymes and proteins in the retinoid or visual cycle
Implementation Method 2
11-cis-Retinal is an endogenous retinoid produced in and by the retinal pigment epithelium (RPE) from the isomerization and oxidation of the all-trans-retinol
Implementation Method 3
11-cis-Retinal functions as a chromophore and convalently binds to the protein opsin to form isorhodopsin
Implementation Method 4
Vision is initiated when a light photon is captured by 11-cis-retinal, resulting in the isomerization to all-trans-retinal
Data Source
AI summary
Disclosed herein are therapeutic regimens for improving visual function in Retinitis Pigmentosa and other visual disorders associated with an endogenous retinoid deficiency in a subject by administering a therapeutically effective amount of a synthetic retinal derivative, for example a 9- or 11-cis retinyl ester, according to the therapeutic regimen which leads to local recovery of visual functions such as visual fields, visual acuity and retinal sensitivity, among others.